retatrutide patent status Retatrutide and the Grey Market:
Description
DTE models help employers address obesity as a core health issue by enabling structured, preventive GLP-1 coverage that can reduce long-term medical costs, disability risk, absenteeism, and productivity losses
GLP-1 RA, glucagon-like peptide 1 receptor agonist
Treatment must be initiated and monitored by specialist weight management services, with specific BMI thresholds and comorbidity requirements
Cost is your primary concern
